From “blockbusters” to “biosimilars”: An opportunity for patients, medical specialists and health care providers

Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic targets. We are switching from predominantly chemical molecules, aimed at treating large populations of patients (blockbuster drugs), to a new...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pulmonary pharmacology & therapeutics Ročník 25; číslo 6; s. 483 - 486
Hlavní autoři: Braido, F., Holgate, S., Canonica, G.W.
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Elsevier Ltd 01.12.2012
Témata:
Asthma
Biological Products - administration & dosage
Biological Products - adverse effects
Biological Products - therapeutic use
Biosimilar Pharmaceuticals - administration & dosage
Biosimilar Pharmaceuticals - adverse effects
Biosimilar Pharmaceuticals - therapeutic use
Biosimilars
Biotech
Drug Design
Drug Industry - methods
Drug Monitoring - methods
Drugs, Generic - administration & dosage
Drugs, Generic - therapeutic use
Humans
Medical Education
Molecular Targeted Therapy
Patents as Topic
Precision Medicine - methods
Pulmonary/Respiratory
Biotech
Biosimilars
Asthma
ISSN:1094-5539, 1522-9629, 1522-9629
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic targets. We are switching from predominantly chemical molecules, aimed at treating large populations of patients (blockbuster drugs), to a new generation of products, mostly biotech, aimed at modifying a specific pathogenetic mechanism. In other word we are moving fast to targeted therapy, which represents the first step toward personalized therapy, where the right drug at the right dose is administered to the right person, at the right time. Like the patent expiration of chemical products has corresponded to the development of generic drugs, the expiration of new biotech products will witness the appearance of biosimilars. The latter are biologic products that are highly similar but not identical to the reference medical products in terms of quality, safety and efficacy. This implies specific research, clinical monitoring, physicians updating of knowledge for a safe and appropriate use of these products. We are the beginning of a devolution in patient's care and physicians' practice.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1094-5539
1522-9629
1522-9629
DOI:10.1016/j.pupt.2012.09.005